MA35188B1 - Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2 - Google Patents

Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2

Info

Publication number
MA35188B1
MA35188B1 MA36577A MA36577A MA35188B1 MA 35188 B1 MA35188 B1 MA 35188B1 MA 36577 A MA36577 A MA 36577A MA 36577 A MA36577 A MA 36577A MA 35188 B1 MA35188 B1 MA 35188B1
Authority
MA
Morocco
Prior art keywords
tetrahydroquinolines
cycloalkylated
modulators
receptor activity
crth2 receptor
Prior art date
Application number
MA36577A
Other languages
English (en)
Inventor
Xianhai Huang
Jason Brubaker
Scott L Peterson
John W Butcher
Joshua T Close
Michelle Martinez
Rachel Nicola Maccoss
Joon O Jung
Phieng Siliphaivanh
Hongjun Zhang
Robert G Aslanian
Purakkattle Johny Biju
Li Dong
Ying Huang
Kevin D Mccormick
Anandan Palani
Ning Shao
Wei Zhou
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35188(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA35188B1 publication Critical patent/MA35188B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne certaines tétrahydroquinolines à fusion cycloalkyle de formule (i) ainsi que leurs sels et esters pharmaceutiquement acceptables, r
MA36577A 2011-06-17 2013-12-17 Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2 MA35188B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498345P 2011-06-17 2011-06-17
PCT/US2012/042336 WO2012174176A1 (fr) 2011-06-17 2012-06-14 Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2

Publications (1)

Publication Number Publication Date
MA35188B1 true MA35188B1 (fr) 2014-06-02

Family

ID=47357455

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36577A MA35188B1 (fr) 2011-06-17 2013-12-17 Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2

Country Status (25)

Country Link
US (2) US20140128367A1 (fr)
EP (1) EP2720545B1 (fr)
JP (1) JP5629403B2 (fr)
KR (1) KR101599157B1 (fr)
CN (1) CN103763924B (fr)
AR (1) AR086931A1 (fr)
AU (1) AU2012271661B8 (fr)
BR (1) BR112013032557A2 (fr)
CA (1) CA2838731C (fr)
CL (1) CL2013003625A1 (fr)
CO (1) CO6821958A2 (fr)
CR (1) CR20130670A (fr)
DO (1) DOP2013000306A (fr)
EA (1) EA025100B1 (fr)
EC (1) ECSP14013156A (fr)
ES (1) ES2613644T3 (fr)
IL (1) IL229508A0 (fr)
MA (1) MA35188B1 (fr)
MX (1) MX2013014900A (fr)
NI (1) NI201300133A (fr)
PE (1) PE20140788A1 (fr)
TN (1) TN2013000471A1 (fr)
TW (1) TW201302711A (fr)
WO (1) WO2012174176A1 (fr)
ZA (1) ZA201308942B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
BR112013015397A2 (pt) 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2922539B1 (fr) 2012-10-01 2020-01-15 Merck Sharp & Dohme Corp. Isoquinolines substituées utiles comme modulateurs du récepteur crth2
CN104761437B (zh) * 2015-03-31 2018-06-19 上海康鹏化学有限公司 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法
CN104829556B (zh) * 2015-05-06 2018-01-23 南京信息工程大学 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法
JP6703090B2 (ja) 2015-07-23 2020-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体アンタゴニストに対する応答に関連した遺伝的マーカー
WO2017209272A1 (fr) * 2016-06-03 2017-12-07 国立大学法人東京大学 Inhibiteur de métastases cancéreuses

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
JPH10506608A (ja) 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド 白血球接着のインヒビター
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
WO1997002289A1 (fr) 1995-07-06 1997-01-23 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5925527A (en) * 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CA2387201C (fr) * 1999-10-14 2009-05-26 Kaken Pharmaceutical Co., Ltd. Derives de tetrahydroquinoline
FR2825092B1 (fr) 2001-05-23 2005-01-14 Servier Lab Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
EP2423190A1 (fr) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Composés présentant un antagonisme du récepteur PGD 2
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040082612A1 (en) 2002-10-15 2004-04-29 Baxter Ellen W Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
CA2500083A1 (fr) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Derives de tetrahydroquinoline antagonistes de crth2
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
WO2005007094A2 (fr) 2003-07-09 2005-01-27 Tularik Inc. Modulateurs d'asthme et d'inflammations allergiques
WO2005100321A1 (fr) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de la prostaglandine d2 pour le traitement de maladies inflammatoires
JP5137240B2 (ja) * 2004-12-27 2013-02-06 アクテリオン ファーマシューティカルズ リミテッド Ｃｒｔｈ２受容体アンタゴニストとしての２，３，４，９−テトラヒドロ−１ｈ−カルバゾール誘導体
KR20070114762A (ko) * 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
AU2006281937B2 (en) 2005-08-12 2011-11-17 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8546422B2 (en) 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
US8637541B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
EP2492267B1 (fr) * 2009-02-24 2014-11-26 Merck Sharp & Dohme Corp. Dérivés d'indole en tant qu'antagonistes du récepteur CRTH2 en combinaison avec un second principe actif
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
BR112013015397A2 (pt) 2010-12-23 2016-09-20 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators

Also Published As

Publication number Publication date
IL229508A0 (en) 2014-01-30
ES2613644T3 (es) 2017-05-25
EA025100B1 (ru) 2016-11-30
ECSP14013156A (es) 2014-02-28
US8592383B2 (en) 2013-11-26
NI201300133A (es) 2014-02-28
EP2720545A4 (fr) 2015-01-14
AU2012271661B2 (en) 2016-11-03
CA2838731A1 (fr) 2012-12-20
CL2013003625A1 (es) 2014-08-01
EP2720545A1 (fr) 2014-04-23
CA2838731C (fr) 2016-08-16
EP2720545B1 (fr) 2016-11-30
AU2012271661A8 (en) 2016-11-10
AU2012271661B8 (en) 2016-11-10
KR20140025576A (ko) 2014-03-04
PE20140788A1 (es) 2014-07-09
JP5629403B2 (ja) 2014-11-19
WO2012174176A1 (fr) 2012-12-20
US20120329743A1 (en) 2012-12-27
CR20130670A (es) 2014-02-04
CN103763924A (zh) 2014-04-30
BR112013032557A2 (pt) 2020-09-24
DOP2013000306A (es) 2014-06-01
KR101599157B1 (ko) 2016-03-02
AR086931A1 (es) 2014-01-29
AU2012271661A1 (en) 2014-01-16
CN103763924B (zh) 2016-05-18
MX2013014900A (es) 2014-02-17
JP2014517041A (ja) 2014-07-17
TW201302711A (zh) 2013-01-16
TN2013000471A1 (en) 2015-03-30
CO6821958A2 (es) 2013-12-31
ZA201308942B (en) 2015-05-27
EA201490031A1 (ru) 2014-12-30
US20140128367A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
MA35188B1 (fr) Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
MA38050B1 (fr) Inhibiteurs de gdf-8
EA201391145A1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
UA111770C2 (uk) Інгібітори бромдомену
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MA37886A1 (fr) Nouvelles pyridinones bicycliques
NZ703162A (en) Heterocyclic modulators of lipid synthesis
SV2014004850A (es) Derivados de benzamida para la inhibición de la actividad de abl1, abl2 y bcr-abl1
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MA37405A1 (fr) Composés hétérocyclyle
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
IN2014MN02106A (fr)
IN2014MN02598A (fr)
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
CR20140134A (es) Composiciones farmacéuticas
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201391524A1 (ru) Производные гликозида и их применение
CU20120064A7 (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
EA201290229A1 (ru) Производные спиролактама и их применение
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні